Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel micelles + cisplatin + 5-fluorouracil + serplulimab
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This chemo-immunotherapy combination regimen is being evaluated by Fudan University for the treatment of locally advanced non-small cell lung cancer (NSCLC). The regimen consists of a nanoparticle formulation of paclitaxel (micelles), the platinum-based alkylating agent cisplatin, the antimetabolite 5-fluorouracil (5-FU), and serplulimab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. In the FANLUNG-2 clinical trial, this combination is utilized as induction therapy in a sandwich model alongside a novel high-low mixed-dose radiotherapy strategy. The approach aims to achieve rapid tumor regression and improve disease control rates while minimizing the risk of radiation-induced pneumonitis by reducing overall lung radiation exposure.
- Brand names
- Hanzhuang
- Other names
- 5-FUCDDPcis-diamminedichloroplatinum(II)paclitaxel micellar
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)
Beyond the preview
Go deeper on paclitaxel micelles + cisplatin + 5-fluorouracil + serplulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel micelles + cisplatin + 5-fluorouracil + serplulimab.